ASH Annual Meeting and Exposition | Conference

Dr. Kelly on Racial Disparities in Multiple Myeloma

January 13th 2017

Kevin R. Kelly, MD, PhD, associate professor of Medicine, Keck School of Medicine, discusses a study examining racial disparities in patients with multiple myeloma.

Dr. Goy on Combination Therapies in Mantle Cell Lymphoma

January 12th 2017

Andre Goy, MD, MS, chairman and director, chief of Lymphoma, and director of Clinical and Translational Cancer Research at John Theurer Cancer Center, discusses combination therapies currently being explored in the treatment of patients with mantle cell lymphoma.

Transplant Remains Pivotal in Myeloma, Other Hematologic Cancers

January 2nd 2017

The use of stem cell transplantation has changed over the last few years, with the emergence of novel therapies and treatment strategies. But even with the FDA approvals of new agents for multiple myeloma and select lymphomas, transplant remains to be a curative and reliable strategy.

Dr. Patnaik on Activity of SL-401 in Chronic Myelomonocytic Leukemia

December 31st 2016

Mrinal Patnaik, MBBS, hematologist, Mayo Clinic, discusses the encouraging results seen in a phase II trial evaluating the activity of SL-401 in patients with advanced, high risk myeloproliferative neoplasms, including chronic myelomonocytic leukemia.

Expert Explains WHO Classification Refinements in Hematologic Malignancies

December 30th 2016

Changes are underway in the field of hematologic malignancies, as the World Health Organization is publishing a revised classification of tumors of hematopoietic and lymphoid tissues—slated to be released in early 2017.

Dr. Mascarenhas on the MPD-RC 112 Study in PV and ET

December 30th 2016

John Mascarenhas, MD, associate professor of Medicine, Mount Sinai School of Medicine, discusses the results from the interim analysis of the MPD-RC 112 study, which compared frontline pegylated interferon-alpha-2a with hydroxyurea in the treatment of patients with high risk polycythemia vera and essential thrombocythemia.

Myeloma Expert Highlights Practice-Changing ASH Findings

December 29th 2016

The landscape of multiple myeloma continues to shift with more drug approvals, but pivotal results out of the 2016 ASH Annual Meeting will likely alter it even further.

Dr. Neelapu on Interim Results of the Phase II ZUMA-1 Study in DLBCL

December 29th 2016

Sattva S. Neelapu, MD, associate professor, Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses interim results of the phase II ZUMA-1 study in patients with diffuse large B-cell lymphoma.

Dr. Daver on Immune Checkpoint Pathways in AML

December 28th 2016

Naval Daver, MD, assistant professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses research evaluating different immune checkpoint pathways in patients with acute myeloid leukemia.

Lenalidomide Shows Activity in Low-Risk MDS

December 22nd 2016

Results from the randomized phase II HOVON89 trial showed that nearly 40% of patients with low intermediate-1 risk myelodysplastic syndrome who were refractory to erythropoietin and granulocyte-colony stimulating factor experienced hematologic improvement with erythroid response after being treated with lenalidomide monotherapy.

Dr. Perales on the PROGRESS II Trial in Hematologic Malignancies

December 22nd 2016

Miguel-Angel Perales, MD, deputy chief, Adult Bone Marrow Transplant Service, director, Adult Bone Marrow Transplantation Fellowship Program, Memorial Sloan Kettering Cancer Center, provides an overview of the PROGRESS II trial, which was conducted for patients with hematologic malignancies.

Dr. Jones on the Efficacy of Venetoclax in Relapsed/Refractory CLL

December 22nd 2016

Jeffrey Jones, MD, MPH, assistant professor of Internal Medicine, Division of Hematology, The Ohio State University, discusses the results of a phase II study that evaluated the efficacy of venetoclax in the treatment of patients with chronic lymphocytic leukemia whose disease had progressed after treatment with either ibrutinib or idelalisib.

Venetoclax Active in Heavily Treated Multiple Myeloma

December 21st 2016

The BCL-2 inhibitor venetoclax (Venclexta) demonstrated activity in one-fifth of patients with heavily pretreated multiple myeloma.

Dr. Takahashi on Biomarker That Predicts Development of Therapy-Related Leukemia

December 21st 2016

Koichi Takahashi, MD, assistant professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses a study exploring a potential biomarker for patients likely to develop therapy-related leukemia.

Benefits of Daratumumab Triplets in Myeloma Sustained With Longer Follow-Up

December 20th 2016

The benefits of 2 FDA-approved daratumumab–based triplet regimens were sustained in long-term data from 2 pivotal phase III studies presented at the 2016 ASH Annual Meeting.

Entospletinib Shows Modest Activity in Mantle Cell Lymphoma

December 20th 2016

Entospletinib was well tolerated and demonstrated modest activity in patients with relapsed or refractory mantle cell lymphoma.

High Rates of Symptoms, Impairment, With Myeloproliferative Neoplasms

December 20th 2016

Patients with myeloproliferative disorders have a high symptom burden that significantly affects emotional status, quality of life, and functional ability.

Ruxolitinib Demonstrates Consistent Survival Benefit in Myelofibrosis

December 19th 2016

Patients with intermediate/high-risk myelofibrosis had improved survival when treated long term with the Janus kinase inhibitor ruxolitinib.

Novel Agent Slows High-Risk Myelofibrosis in Initial Trial

December 19th 2016

A third of patients with previously treated, high- and intermediate-risk myelofibrosis had objective responses to the investigational Second mitochondria-derived activator of caspases mimetic LCL161.

Gene Expression Studies Offer Insight Into Myeloma Regimen's Efficacy

December 19th 2016

An analysis of c-MYC expression in relapsed myeloma identified subgroups of patients with improved response to the combination of an immunomodulator and a proteasome inhibitor.